Business Context and Reporting Period
This Form 8-K, filed on February 21, 2025, by Bio-Rad Laboratories, Inc. (Bio-Rad), serves as a Regulation FD disclosure. It provides an update regarding Bio-Rad's investment in Sartorius AG, referencing Sartorius's financial results for the year ended December 31, 2024, which were publicly disclosed by Sartorius on February 17, 2025.
Key Financial Metrics of Sartorius AG
The filing summarizes Sartorius AG's financial data for the year ended December 31, 2024, in millions of Euros (€), prepared under IFRS:
| Metric | Value (€ Millions) |
|---|---|
| Sales Revenue | 3,380.7 |
| Gross Profit | 1,524.4 |
| EBIT | 392.6 |
| Net Profit | 137.4 |
| Operating Cash Flow | 976.2 |
| Investing Cash Flow | (425.8) |
| Financing Cash Flow | (128.3) |
| Total Assets (Current + Non-current) | 10,103.0 |
| Total Liabilities (Current + Non-current) | 6,205.2 |
| Equity | 3,897.8 |
Note: This filing does not provide specific financial metrics for Bio-Rad Laboratories, Inc. itself, only for its investee, Sartorius AG.
Material Changes and Comparisons
The filing text does not provide comparative financial data for Sartorius AG for the prior period (2023) or year-over-year percentage changes. It solely presents the absolute figures for the 2024 fiscal year.
Guidance, Risks, and Contingencies
Management Commentary and Disclaimer: Bio-Rad explicitly states it does not assume any responsibility or liability for errors or omissions in the information publicly disclosed by Sartorius AG. The data is referenced solely to update the investment disclosure originally made in Bio-Rad's 2024 Form 10-K.
Further Information: Investors are directed to Sartorius AG's 2024 Annual Report for further details. The Sartorius website is not incorporated by reference into this report.
Key Facts for Investor Verification
- Verify the full 2024 Annual Report of Sartorius AG for detailed segment performance and risk factors not included in this summary.
- Confirm the exchange rate used to convert Sartorius's Euro-denominated results to USD for Bio-Rad's consolidated financial statements.
- Review Bio-Rad's Form 10-K (filed February 14, 2025) to understand the accounting method (e.g., equity method) used to record the investment in Sartorius.
- Note that this 8-K contains no new operational guidance or financial results for Bio-Rad Laboratories, Inc. itself.